 BURLINGAME, Calif., Feb. 17, 2021 GLOBE NEWSWIRE -- Corvus Pharmaceuticals, Inc. NASDAQ:CRVS, a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212,231 shares of common stock pursuant to the underwriters partial exercise of their option to purchase additional shares of common stock, at a price to the public of 3.50 per share. All shares in the offering were sold by Corvus, with gross proceeds to Corvus of 34.2 million and net proceeds of approximately 31.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. 